Canadian biopharma company Algernon Pharmaceuticals Inc. AGNPF’s subsidiary Algernon NeuroScience (AGN Neuro) completed dosing the second cohort of its Phase 1 study on the company’s proprietary IV ...
NEW YORK, July 28, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics TM ”, today announced ...
VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an ...
Benjamin holds a Master's degree in anthropology from University College London and has previously worked in the fields of psychedelic neuroscience and mental health. Benjamin holds a Master's degree ...
Columnist Ben Hofmeister says he's extremely grateful for Ocrevus infusions, which have so far halted his MS disease activity.
In a new study, scientists at Imperial College London investigated how powerful psychedelic dimethyltryptamine (DMT) alters the brain’s electrical activity. One of the main psychoactive substances in ...
N, N-Dimethyltryptamine (DMT) is famous for producing one of the most intense psychedelic experiences possible, catapulting users into a series of vivid, incapacitating hallucinations. But despite the ...
DMT could be a more cost-effective treatment for depression, addiction and other conditions. Tripping on DMT usually lasts under one hour, while psychedelic psilocybin lasts up to eight. DMT is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback